VTVT - vTv Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
1.8400
-0.1300 (-6.60%)
At close: 4:00PM EDT

1.8500 +0.01 (0.54%)
After hours: 4:55PM EDT

Stock chart is not supported by your current browser
Previous Close1.9700
Open1.9300
Bid1.8400 x 800
Ask1.8500 x 800
Day's Range1.8300 - 1.9700
52 Week Range0.6500 - 6.0900
Volume408,174
Avg. Volume2,424,480
Market Cap85.932M
Beta (3Y Monthly)-6.17
PE Ratio (TTM)N/A
EPS (TTM)-0.6950
Earnings DateOct 31, 2017 - Nov 6, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
Trade prices are not sourced from all markets
  • Triad biopharmaceutical company seeks to raise $6 million
    American City Business Journalsyesterday

    Triad biopharmaceutical company seeks to raise $6 million

    A rollercoaster year in 2018 saw the company's stock fall dramatically, but successful testing of potential drugs late in the year helped the stock price recover handily heading into a so far more stable 2019.

  • Business Wire2 days ago

    vTv Therapeutics Announces $15 Million of Class A Common Stock Financings

    vTv Therapeutics Inc. (VTVT) (the “Company”) today announced that it has entered into a definitive agreement with certain institutional investors for the purchase and sale in a registered direct offering (the “Registered Direct Offering”) of 3,636,364 shares of the Company’s Class A common stock (the “Common Stock”) at a price of $1.65 per share for aggregate gross proceeds of approximately $6.0 million. H.C. Wainwright & Co. is acting as the exclusive placement agent. The Company also entered into a letter agreement (the “Letter Agreement”) with MacAndrews & Forbes Group LLC (“M&F Group”), the Company’s largest shareholder, pursuant to which M&F Group has committed to purchase, at the Company’s option and exercisable on demand during a one-year period after the date of the Letter Agreement, up to 5,454,545 unregistered shares of Common Stock at a fixed price of $1.65 per share for aggregate proceeds of approximately $9.0 million assuming the Company elects to sell the entire amount.

  • Business Wire21 days ago

    vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update

    vTv Therapeutics Inc. today reported financial results for the fourth quarter and year that ended December 31, 2018, and provided an update on recent achievements and upcoming events.

  • ACCESSWIRE2 months ago

    Watch These 4 Healthcare Stocks Set the Pace on Friday (1/25/19)

    Companies in the healthcare industry have recognized that, as medical experts discover more diseases and ailments, this creates an opportunity to invest in products/services to improve the quality of life for patients. Premier Health Group (OTC:PHGRF) (CSE:PHGI), vTv Therapeutics Inc (VTVT), Canopy Growth Corp (CGC) (WEED.TO), and Rewalk Robotics Ltd (RWLK) represent four healthcare companies determined to invest in the betterment of healthcare. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company focused on developing nuanced approaches that combine human skill-based expertise with up and coming technologies for the healthcare industry to create optimal care solutions for their patients.

  • Business Wire2 months ago

    vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study

    vTv Therapeutics Inc. (VTVT) today announced the publication of a paper in Science Translational Medicine showcasing the discovery and development of TTP399, an investigational, oral, small molecule, liver-selective glucokinase (GK) activator, as a potential treatment for diabetes. The paper reviews the scientific rationale underpinning the development of TTP399 and its progression from preclinical to clinical development concluding with the positive results of the AGATA study, a phase 2 study of TTP399 in patients with type 2 diabetes. No hypoglycemia, no detrimental effects on plasma lipids or liver enzymes, and no increased blood pressure were observed with TTP399 relative to placebo, highlighting the importance of tissue selectivity and preservation of physiological regulation when targeting key metabolic regulators such as GK.

  • 10 trading lessons for 2019 that we learned from the 2018 stock market selloff
    Yahoo Finance3 months ago

    10 trading lessons for 2019 that we learned from the 2018 stock market selloff

    Every year there are opportunities to learn from winners and losers in the market. 2018 was at once extraordinary and normal.

  • ACCESSWIRE3 months ago

    Watch These Top Trending Stocks On Jan. 2, 2019

    CORAL GABLES, FL / ACCESSWIRE / January 2, 2019 / This past year has been wild for the stock market, but now that we're a few days into the new year, possibilities in the space are endless. As sectors across all industries try and start off the year as strong as possible, this week's investors are being presented with several stocks providing volatile upswings just after the new year. As we move, headfirst into the new year, Premier Health Group (OTC:PHGRF) (CSE:PHGI), Prana Biotechnology Limited (NASDAQ: PRAN), Safe-T Group Ltd (NASDAQ: SFET), and vTv Therapeutics Inc (NASDAQ: VTVT) are presenting investors with potential opportunities just after the break of the new year.

  • ACCESSWIRE3 months ago

    Biotech Rally Ahead of the Market

    HENDERSON, NV / ACCESSWIRE / January 2, 2019 / Biotech hit its bear market phase weeks before the market as a whole did. Some analysts think this means the turnaround will come sooner. Here's a few biotech ...

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks That Are Raising Eyebrows

    CORAL GABLES, FL / ACCESSWIRE / December 31, 2018 / With the new year only a few short moments away, the healthcare sector is electrified with excitement given that industry has shown tremendous growth over the last few months, as experts and professionals in the field have worked on developing technologies to improve the quality of care for patients on a global scale. Premier Health Group (PHGRF) (PHGI), Akers Biosciences Inc (AKER), vTv Therapeutics Inc (VTVT), and Achillion Pharmaceuticals, Inc (ACHN) represent 4 healthcare stocks to watch on Monday. Premier Health Group (PHGRF) (PHGI) is a company that is dead-set on investing in the development of innovative, high tech treatment solutions for patients in the primary care space.

  • ACCESSWIRE3 months ago

    Biotech Companies in the News

    HENDERSON, NV / ACCESSWIRE / December 31, 2018 / Several biotech companies have released major announcements this holiday season setting themselves up for a strong start to 2019. We are highlighting: Endonovo ...

  • ACCESSWIRE3 months ago

    4 Healthcare Stocks Gaining Speed on Friday (12/28/18)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), Opko Health Inc (OPK), vTv Therapeutics Inc (VTVT), and Teladoc Health Inc (TDOC) are 4 healthcare stocks that could test their December highs on Friday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company laser-focused on meeting the increasing demands and expectations of the healthcare industry.

  • GlobeNewswire4 months ago

    Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Business Wire4 months ago

    vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference

    vTv Therapeutics Inc. today announced that company management will present a corporate overview at the Piper Jaffray 30th Annual Healthcare Conference on Tuesday, Nov.

  • VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
    Zacks4 months ago

    VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates

    vTv Therapeutics (VTVT) delivered earnings and revenue surprises of 60.00% and 63.84%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press4 months ago

    VTv Therapeutics: 3Q Earnings Snapshot

    The High Point, North Carolina-based company said it had a loss of 6 cents per share. The biopharmaceutical company posted revenue of $3.4 million in the period. In the final minutes of trading on Thursday, ...

  • Business Wire4 months ago

    vTv Therapeutics Announces Third Quarter 2018 Results and Update

    vTv Therapeutics Inc. today reported financial results for the third quarter that ended September 30, 2018, and provided an update on recent achievements and upcoming events.

  • VTv Therapeutics (VTVT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks5 months ago

    VTv Therapeutics (VTVT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    VTv Therapeutics (VTVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Business Wire5 months ago

    vTv Therapeutics Announces Transfer of Listing to The Nasdaq Capital Market

    vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that The NASDAQ Stock Market LLC (“Nasdaq”) has approved the Company’s application to list its Class A Common Stock on The Nasdaq Capital Market. The Company’s securities will be transferred from The Nasdaq Global Market to The Nasdaq Capital Market at the opening of business on October 30, 2018. The Nasdaq Capital Market is a continuous trading market that operates in substantially the same manner as The Nasdaq Global Market and listed companies must meet certain financial requirements and comply with Nasdaq’s corporate governance requirements.

  • Business Wire5 months ago

    vTv Therapeutics Presents Positive Data on the Effect of Azeliragon in Patients with Alzheimer’s and Diabetes at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

    vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that a subgroup analysis from the azeliragon Phase 3 STEADFAST trial was presented at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference in Barcelona, Spain. The data presented at the conference included post-hoc, positive data indicating a potential benefit of treatment with azeliragon in AD patients with type 2 diabetes. It is estimated that nearly 40 percent of Medicare beneficiaries age 65 and older with dementia also have diabetes (Alzheimer’s Association.

  • Market Exclusive5 months ago

    Stock Market News Daily Roundup October 17

    Shares of International Business Machines (NYSE: IBM) are down 5% today as the company topped Wall Street expectations for third-quarter earnings but missed Street estimates for revenue. The company reported a total revenue of $18.76 billion, down from $19.15 billion a year ago. Analysts estimated $19.10 billion in revenue for the third quarter. Netflix, Inc. […] The post Stock Market News Daily Roundup October 17 appeared first on Market Exclusive.

  • ACCESSWIRE5 months ago

    Today's Research Reports on Trending Tickers: vTv Therapeutics and Johnson & Johnson

    NEW YORK, NY / ACCESSWIRE / October 17, 2018 / U.S. equities closed higher on Tuesday, driven by upbeat corporate earnings and strong economic data. According to the Federal Reserve, U.S. industrial production ...

  • Business Wire5 months ago

    vTv Therapeutics to Deliver Two Presentations at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

    vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will deliver an oral presentation and present a poster at the 11th Clinical Trials on Alzheimer’s Disease (CTAD) conference on October 24-27, 2018 in Barcelona, Spain. The oral presentation will detail the results from the phase 3 STEADFAST study of azeliragon in patients with mild Alzheimer’s disease.

  • ACCESSWIRE5 months ago

    vTv Therapeutics Shares Soar in October, Near Term Catalysts, Analysts review and Target

    NEW YORK, NY / ACCESSWIRE / October 15, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on vTv Therapeutics Inc. (VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates. Despite the lack of company news or announced catalyst, VTVT shares have jumped from $.78 per share to the current price of $3.45 thus far in October. Since its recent announcement regarding the topline results from Part B of the STEADFAST Study, VTVT has continued to analyze the results from Parts A and B and are encouraged by its findings.

  • vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session
    Zacks5 months ago

    vTv Therapeutics (VTVT) Looks Good: Stock Adds 5.8% in Session

    vTv Therapeutics (VTVT) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.